Gardasil 9
An application has been made by Seqirus Australia to the Pharmaceutical Benefits Advisory Committee to list Gardasil 9 on the National Immunisation Program as a 2-dose schedule for females and males aged 12-13 years as part of a school age program for the prevention of the human papilloma virus HPV. This listing if approved will replace the current 3-dose schedule of Gardasil, the 4-valent HPV vaccine. The committee whose role […]
helenlobato.com 